Mucormycosis and aspergillosis: The deadly duo in COVID-19-a case report.
| Autor: | Mohanty B; Department of Medicine, Jamshedpur, Jharkhand, India., Ansari Z; Department of Medicine, Jamshedpur, Jharkhand, India., Prasad A; Department of Pathology, Jamshedpur, Jharkhand, India., Gupta M; Department of Pathology, Jamshedpur, Jharkhand, India., Kumar A; ENT, Tata Main Hospital, Jamshedpur, Jharkhand, India. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of family medicine and primary care [J Family Med Prim Care] 2022 Oct; Vol. 11 (10), pp. 6529-6532. Date of Electronic Publication: 2022 Oct 31. |
| DOI: | 10.4103/jfmpc.jfmpc_359_22 |
| Abstrakt: | COVID-19 disease has been associated with fungal infections such as aspergillosis and mucormycosis, especially in diabetic patients who have suffered from a moderately severe form of COVID-19 infection and are treated with steroids. Though there are multiple case reports describing co-infection with mucormycosis during the second wave of the COVID outbreak, the report of a dual fungal infection along with superadded bacterial infection is rare. Here we report a case where the same patient had a fungal storm with aspergillosis and mucormycosis and superadded Klebsiella . She was treated aggressively with antifungal agents, antibiotics, surgical debridement, and other supportive care. She improved and was discharged from the hospital after a long stay. She is being followed up regularly in the outpatient department and doing well. Competing Interests: There are no conflicts of interest. (Copyright: © 2022 Journal of Family Medicine and Primary Care.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|